These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 16294366

  • 1. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
    Mulder H, Herder A, Wilmink FW, Tamminga WJ, Belitser SV, Egberts AC.
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.
    Mulder H, Heerdink ER, van Iersel EE, Wilmink FW, Egberts AC.
    Ann Pharmacother; 2007 Mar; 41(3):408-13. PubMed ID: 17341534
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Roberts RL, Mulder RT, Joyce PR, Luty SE, Kennedy MA.
    Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
    [Abstract] [Full Text] [Related]

  • 6. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
    Kobylecki CJ, Jakobsen KD, Hansen T, Jakobsen IV, Rasmussen HB, Werge T.
    Neuropsychobiology; 2009 Jan; 59(4):222-6. PubMed ID: 19521114
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.
    Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M, Eschenhagen T.
    Clin Pharmacol Ther; 2004 May; 75(5):386-93. PubMed ID: 15116051
    [Abstract] [Full Text] [Related]

  • 10. Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?
    Laika B, Leucht S, Heres S, Steimer W.
    Pharmacogenomics J; 2009 Dec; 9(6):395-403. PubMed ID: 19451914
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA.
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [Abstract] [Full Text] [Related]

  • 12. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
    Szewczuk-Bogusławska M, Grzesiak M, Beszłej JA, Kiejna A.
    Psychiatr Pol; 2004 Dec; 38(6):1093-104. PubMed ID: 15779673
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
    Jukic MM, Smith RL, Haslemo T, Molden E, Ingelman-Sundberg M.
    Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK, Zalar B, Breskvar K, Dolzan V.
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [Abstract] [Full Text] [Related]

  • 18. The association between cytochrome P450-2D6 genotype and prescription of antiparkinsonian drugs in hospitalized psychiatric patients using antipsychotics: a retrospective follow-up study.
    Mulder H, Wilmink FW, Belitser SV, Egberts AC.
    J Clin Psychopharmacol; 2006 Apr; 26(2):212-5. PubMed ID: 16633157
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.